1928 Diagnostics is a leading brand comprised of a dedicated team of software developers, bioinformaticians, microbiologists, and quality engineers who are actively combatting antibiotic resistance. Passionate about improving infection diagnostics worldwide, they work closely with end users to develop a comprehensive and user-friendly bioinformatics analyses platform that utilizes sequencing technology to its fullest potential. Their expertise in biochemistry, molecular biology, molecular pharmacology, and regulatory requirements ensures that they deliver high-quality results.

Headed by Dr. Susanne Staaf, the CEO and founder, the team also boasts accomplished individuals like Johan Ehn, the CCO, Fredrik Dyrkell, the CTO, and Silvia Borghesi, the Key Account Manager, among others. With a wide range of experience and knowledge in their respective fields, they are well-equipped to meet the present and future needs of infection control.

1928 Diagnostics also has a strong board of directors and advisors, including industry experts such as Jens Mogensen, the Chairman of the Board, and Prof. Christian Giske, a renowned Professor in Clinical Bacteriology. This diverse team ensures that the brand remains at the forefront of the fight against antibiotic resistance.

For more information and updates from 1928 Diagnostics, users can sign up for their newsletter. With headquarters in Mölndal, Sweden, and a US office in New York, they have a global reach and are committed to making a significant impact in the field of infection diagnostics